Ahmed Sameh Abdelkhalik, Selim Amal, Hawash Nehad, Tawfik Ahmed Khaled, Yousef Mohamed, Kobtan Abdelrahman, Badawi Rehab, Elnawasany Sally, Elkhouly Reham Abdelkader, Hanafy Amr Shaaban, Rizk Fatma H, Mansour Loai, Abd-Elsalam Sherief
Department of Anesthesia, Tanta University, Tanta, Egypt.
Internal Medicine Department, Tanta University, Tanta, Egypt.
Int J Hepatol. 2017;2017:8462756. doi: 10.1155/2017/8462756. Epub 2017 Sep 26.
We aimed to investigate the safety and efficacy of propofol plus fentanyl versus midazolam plus fentanyl as sedative for patients with advanced liver disease presented for gastrointestinal endoscopy.
A total of 100 patients with liver cirrhosis referred for upper endoscopy were enrolled and divided equally in two groups, midazolam plus fentanyl group and propofol plus fentanyl group. All patients were subjected to history taking, estimation of level of sedation, endoscopist rating, and hemodynamic parameters including oxygen saturation, heart rate, mean arterial pressure, incidence of side effect as (bradycardia, hypotension, hypoxia, nausea and vomiting, cough, shivering, or diplopia), time needed for complete recovery, and time needed for discharge.
There was no statistical significant difference between the studied groups regarding age, sex, weight, Child-Pugh classification score, type and duration of endoscopic intervention, time needed for complete recovery, or time needed for discharge. Complication rates were similar in both groups except for mean arterial blood pressure which was significantly lower in group of patients receiving propofol and fentanyl ( = 0.001).
The use of either propofol or midazolam in combination to fentanyl is effective in sedation of patients with advanced liver diseases presented for upper GIT endoscope. The trial is registered with ClinicalTrials.gov Identifier: NCT03063866.
我们旨在研究丙泊酚联合芬太尼与咪达唑仑联合芬太尼作为镇静剂用于晚期肝病患者进行胃肠内镜检查时的安全性和有效性。
共有100例因上消化道内镜检查而转诊的肝硬化患者入组,并平均分为两组,即咪达唑仑联合芬太尼组和丙泊酚联合芬太尼组。所有患者均接受病史采集、镇静水平评估、内镜医师评分以及血流动力学参数监测,包括血氧饱和度、心率、平均动脉压、副作用发生率(如心动过缓、低血压、低氧血症、恶心呕吐、咳嗽、寒战或复视)、完全恢复所需时间以及出院所需时间。
在研究组之间,关于年龄、性别、体重、Child-Pugh分级评分、内镜干预的类型和持续时间、完全恢复所需时间或出院所需时间,均无统计学显著差异。两组的并发症发生率相似,但接受丙泊酚和芬太尼的患者组的平均动脉血压显著较低(P = 0.001)。
丙泊酚或咪达唑仑联合芬太尼用于晚期肝病患者进行上消化道内镜检查时的镇静是有效的。该试验已在ClinicalTrials.gov注册,标识符为:NCT03063866。